Status:
UNKNOWN
Ventricular Remodelling and Metabolomics in Pediatric Cardiomyopathies (PROGRESS-OMICS)
Lead Sponsor:
Bambino Gesù Hospital and Research Institute
Collaborating Sponsors:
Parent Project, Italy
Ministry of Health, Italy
Conditions:
Cardiomyopathies
Pediatric ALL
Eligibility:
All Genders
1-18 years
Brief Summary
The pathogenesis of cardiomyopathies is complex and a simple approach cannot describe the whole picture. Different etiologies are reported in pediatric age and heart failure onset can lead to poor pro...
Eligibility Criteria
Inclusion
- Patients with Cardiomyopathies
- Dilated Cardiomyopathy, defined as left ventricular dilation \> 2SD
- A-D stages of Heart Failure, according to ACC/AHA definition
- \< 18 years
Exclusion
- Restrictive cardiomyopathy
- Hypertrophic cardiomyopathy
- Congenital Heart Diasease
- Valvular Heart Disease, as primary cause of heart failure
- \> 18 years
- Control Group
- Inclusion Criteria:
- Children without familial disease and/ or abnormalities of ECG and echocardiographic, NT pro BNP ≥ 103 pg/mL, TnT ≥ 14
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04670731
Start Date
February 1 2021
End Date
June 1 2022
Last Update
February 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bambino Gesù Hospital and Research Institute
Rome, Italy